Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Biotech Showcase 2020
41 slides from Genetic Technologies's conference presentation, Jan 13, 2020
Slide 1: About Genetic Technologies Limited
About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Can
Slide 2: Biotech Showcase, San Francisco, 14 January 2020
NASDAQ: GENE Biotech Showcase 14 January 2020 San Francisco
Slide 3: Forward looking statements
Forward looking statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance
Slide 4: Who we are
Who we are Genetic Technologies is a leader in genomics • • • Over a decade of R&D surrounding the development of polygenic risk scores Developing risk prediction platforms for major oncological, metabolic and degenerative diseases Strong scientific leadership under Dr Richard Allman – a pioneer in
Slide 5: The human genome
The human genome In 2003, humanity completed perhaps its most ambitious voyage of exploration when scientists mapped the human genome – the three-billion-plus pairs of DNA that make us human. Advances in genomic epidemiology and sequencing technology will influence the way physicians practice medici
Slide 6: Polygenic Risk Score: What is it?
Polygenic Risk Score What is it? • • Most common complex diseases are a result of not one or a few genes, but many acting in concert Polygenic Risk Score is a DNA based risk assessment (screening) tool that weighs a person’s odds developing common complex diseases by inspecting DNA information sprea
Slide 7: Polygenic Risk Score vs genetic testing
Polygenic Risk Score How do Polygenic Risk Scores differ from genetic testing (e.g. BRCA in breast cancer)? • • • Genetic testing only captures hereditary forms of disease (e.g. inherited cancer risk) Polygenic Risk Scores capture sporadic (non-inherited) disease, the most common form It allows for
Slide 8: Justification of Polygenic Risk Score for earlier screening
The justification of using Polygenic Risk Score to inform earlier screening is similar across disease types Breast cancer Colorectal cancer Coronary heart disease Jenkins et al. (2019) Familial Cancer Abraham et al. (2016) Eur Heart J. Mavaddat et al. (2015) JNCI 7
Slide 9: The unmet need
The unmet need • • • • • • Current genetic testing only captures hereditary forms of disease Current system is binary - everyone is tested regardless of personal risk status Currently system is inefficient with a one-size-fits-all policy based on averages Unable to clearly identify high risk groups
Slide 10: Intellectual property is a core advantage
Intellectual property is a core advantage GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in the US 7 Patent families pending • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus®
Slide 11: Operational overview
Operational overview Genetic Technologies Limited Melbourne, Australia • Technical and corporate support • CLIA approved laboratory Phenogen Sciences Inc. Charlotte, North Carolina, USA • Clinical and customer support • Sales and marketing • Liaison for US collaboration 10
Slide 12: Our board
Our board Dr. Jerzy “George” Muchnicki MBBS Executive Director & Chief Executive Officer (Interim) Dr. Lindsay Wakefield MBBS Non – Executive Director Mr Nick Burrows B.Com, FAICD, FCA, FGIA, FTIA, F Fin Non – Executive Director Mr. Peter Rubinstein BSc, BEc, LLB Non – Executive Director 11
Slide 13: Our vision
Genetic Our vision Technologies Identify and manage patients who are at high risk of developing major life threatening diseases Implement the current protective medical strategies in the best way possible for identified high risk groups via: * targeted screening + lifestyle changes + chemoprophylaxi
Slide 14: Product range and status
Product range and status • • Our breast and colorectal cancer products are market ready T2D and CV tests are in final stages of development 2Q 2019 1Q 2020 Cardiovascular 3Q 2020 Test validation 4Q 2020 Prostate Cancer Melanoma * Tests are developed and 14 market launch is scheduled. Cardiovascular
Slide 15: Disease coverage
Disease coverage • Our product development strategy aims to provide coverage of the most significant causes and mortality in the US of morbidity • It covers up to 70% of causes of mortality Incidence of underlying causes of mortality in the US Breast Cancer Colorectal Cancer Type 2 Diabetes Cardiova
Slide 16: GeneType for Breast Cancer
GeneType for Breast Cancer 16
Slide 17: Breast cancer at a glance
Breast cancer at a glance • • 1 in 8 women will get breast cancer in their lifetime Every year approximately 270,000 women will be diagnosed with breast cancer 25% of breast cancers develop before the age of 50 (average age 62) 85% of women have no family history of breast cancer 10% have a family h
Slide 18: Average (asymptomatic) woman at a glance
Average (asymptomatic) woman at a glance • • Majority of women do NOT have family history of breast cancer Misconception that lack of FH means lower risk of breast cancer thus they tend be less screen-compliant Percentage of women (40+) with dense breast tissue Up-to-date mammogram Nearly half of al
Slide 19: GeneType for Breast Cancer
GeneType for Breast Cancer • GeneType for Breast Cancer (GeneTypeBC) is a first-to-market, clinically validated genetic risk assessment for non-hereditary (sporadic) breast cancer which represents up to 90% of all breast cancers It is the world’s first validated genomic test to accurately predict ri
Slide 20: Targeted screening and prevention
Targeted screening and prevention Screening More frequent mammograms or MRIs GeneType for Breast Cancer enables the targeting of limited resources to women who are most likely to develop breast cancer Medication Selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) Lifestyle W
Slide 21: Identify at-risk women = Better outcomes
Identify at-risk women = Better outcomes Screening By implementing enhanced surveillance of high-risk individuals, you enable clinicians to improve breast cancer detection 5-year survival rates dramatically improve when breast cancer is diagnosed before spreading to Risk reduction • • By qualifying
Slide 22: Early diagnosis = Less expensive treatment
Early diagnosis = Less expensive treatment Stage I…………………….$ 55,000 First year treatment for breast costs cancer Stage II……………..…….$103,000 Stage III and IV………….$150,000+ USD, study based on US patients, 2003-2010 https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0207993.t001
Slide 23: Wider age and population coverage
Wider age and population coverage • GeneType for Breast Cancer tests individuals before age of 35 and covers the African American and Hispanic population 23
Slide 24: GeneType for Colorectal Cancer
GeneType Colorectal for Cancer 24
Slide 25: Colorectal cancer at a glance
Colorectal cancer at a glance • 150,000 people are diagnosed with colorectal cancer every year in US More than 50% of colorectal cancer are first identified in late stage 69% 5-year survival rate Late stage survival • 1 in 20 will get colorectal cancer in their Screening begins at 45 lifetime • • •
Slide 26: Lifetime risk stratified by polygenic risk and family history
Distribution of lifetime stratified by polygenic colorectal cancer risk risk and family history • Risk of acquiring the disease as a high-risk individual is earlier Family history is potent in identifying risk • • Can't look at genomics alone 26 Jenkins MA, Win AK, Dowty JG, et al: Ability of known
Slide 27: World-first polygenic risk test for colorectal cancer
GTG has developed a world-first polygenic risk test for colorectal cancer Easy-to-use test solves the compliance problem Risk stratification enables precision screening and personalised prevention Clinically actionable results 5-year, 10-year and lifetime risk Informs screening and health monitoring
Slide 28: Commercialization Strategy
Commercialization Strategy
Slide 29: Touching as many lives as possible through partnerships
We aim to touch as many lives as possible through partnerships (network) Partnership Partner with genomics market leaders to integrate Genetic Technologies’ tests into their testing platforms: Clinics/CIT Q1 2020 Launch GeneType product line: • • • Consumer initiated $249 price point Leverage existi
Slide 30: Partnering as an OEM/white label test
Partnering as an OEM/white label test Genetic Technologies is seeking to market its polygenic risk score tests as part of a wider offering by established genomic testing market leaders Our partner should : • • Be a market leader in CIT or DTC genomics space Have a large pool of genomes available for
Slide 31: Consumer Initiated Testing
Consumer Initiated Testing More people are taking control of their health CIT Will allow Genetic Technologies to offer Polygenic Risk Score tests directly to consumers • Genetic Technologies is in discussions with a leading provider of CIT services that will Provide outsourced clinical and logistica
Slide 32: Existing network of clinics
Existing network of clinics • • Genetic Technologies plans to leverage existing relationships with its network of clinics Strong demand from clinicians familiar with the products and the value proposition of Polygenic Testing Risk • • • Clinics used to offer Genetic Technologies’ previous 20+ clinic
Slide 33: Validation, Collaboration and Academic Partnerships
Validation, Collaboration and Academic Partnerships
Slide 34: Translational Genomics Research Institute (TGen): Background
Translational Genomics Research Institute (TGen): Background Collaborative Network Areas of Disease Focus - - - - - Est. 2002 Non-profit (501c3) Patient-focused clinical & basic research Pioneers in precision genomic medicine Expertise includes: Clinicians, laboratory and computer scientists, data a
Slide 35: Collaboration is a key market advantage
Collaboration is a key market advantage The University of Melbourne •Australia’s peak research-intensive institution, ranked 32nd globally Our collaboration with The University of Melbourne was awarded an NHMRC grant • • • Research investigation to assess the improvement in breast cancer risk predic
Slide 36: Research into clinical applications
Research into clinical applications GTG has an agreement in place with Memorial Sloan Kettering (MSK) and University of Cambridge • • • • The research is led by Mark E. Robson, MD, Chief of Breast Medicine Service, Memorial Sloan Kettering MSK is the world’s oldest and largest cancer treatment and r
Slide 37: Other key partnerships
Other key partnerships Ohio State University (Columbus, Ohio) •Research collaboration exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations •Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast cancer assessment risk Nur
Slide 38: Genetic Technologies' snapshot
Genetic Technologies’ snapshot • • • • • Current market cap as of 9/01/2020: $27.9M Dual listed ASX/NASDAQ App. No. Shares on issue: 4,000,000,000 (ADR @ 600:1) $US 3M cash as of 31 December 2019 Company funded out to Q1 2021 based on current business plan 38
Slide 39: An exciting year ahead for Genetic Technologies
An exciting year ahead for Genetic Technologies Upcoming catalysts aim to increase revenues and generate shareholder value • • • GeneType for Breast Cancer and GeneType for Colorectal cancer Start US Sales and marketing through existing clinician network Start of clinical utility study in conjunctio
Slide 40: Thank you
Thank you Dr George Muchnicki Executive Director and Interim george.muchnicki@gtglabs.com www.gtglabs.com CEO 40
Slide 41: Thank you
Genetic Technologies Thank you Dr George Muchnicki Executive Director and Interim CEO george.muchnicki@gtglabs.com www.gtglabs.com